Top Banner
Genetics of Vascular Diseases Jake Lusis 3-730 MRL [email protected]
39
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Genetics of Vascular Diseases

Jake Lusis3-730 MRL

[email protected]

Page 2: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.
Page 3: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

210

410 200 210 180 430

420190460490

Carl Miller, ~1938, Oslo County Hospital, Norway

Inheritance of:

Cholesterol level (mg/dl):

Tendon xanthomas:

Early coronary artery disease (under 55 years of age):

330 210

Page 4: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Tendon Xanthomas

Cosegregation of triad of xanthomas, high cholesterol and early heart disease

Page 5: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

210190 400

210 430 490420 180

170420

Inheritance of:

Cholesterol level (mg/dl):

Tendon xanthomas:

Early coronary artery disease (under 55 years of age):

210 230

810 420

This individual died from severe CAD at age 7

Page 6: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Lecture delivered in Sweden Dec 9, 1985 when they received the Nobel Prize in Physiology. Published in

Science, 232, 34-47, 1986

Page 7: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Experiments with 125I-LDL and skin fibroblasts

skin fibroblasts from normal and FH individuals

add labeled 125I-LDL ( )

incubate to allow binding

wash away unbound LDL and follow label

- 125I-LDL on surface can be displaced from cells by anionic polymers

- 125I-LDL that has been internalized cannot be displaced from cells

- 125I-LDL that has been degraded to amino acids is soluble in tricholoroacetic acid

Page 8: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

FH homozygote

Normal

Experiments with fibroblasts from normal and FH individuals

Page 9: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Sequential steps in LDL receptor pathway: Discovery of receptor mediated endocytosis

Page 10: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Degradation of LDL by lymphocytes and following injection

Page 11: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Cloning of the Human LDL Receptor

cultured skin fibroblastsisolate plasma membrane

purify such that a single protein remains upon electrophoresis

extract proteins with detergent and subject to chromatography

125I-LDL bound

digest the protein and sequence the resulting

peptides

-ASN-PHE-THR-SER-based on the amino acid

sequence, synthesize corresponding oligonucleotide

probes

….CACTCGACAGCGAAC...

probe cDNA and genomic libraries.

Confirm identity of clones by sequencing

and expression studies

Page 12: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Domain structure of the LDL receptor

Page 13: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Five classes of LDL receptor mutations

Page 14: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Development of drugs to treat hypercholesterolemia based on concepts learned from FH studies

Page 15: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Combined heart-liver transplant in an individual with homozygous FH

Page 16: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Lessons from familial hypercholesterolemia

• Studies of an uncommon disease (FH) can have important implications for a common disease (coronary artery disease)

• Genetics studies of clinical traits can lead to an understanding of basic biologic mechanisms (receptor mediated endocytosis, cholesterol homeostasis) as well as new therapies (statins).

Page 17: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Francis Collins (1995)

Page 18: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Schematic of the approach generally utilized for positional cloningSchematic of the approach generally utilized for positional cloning

FamiliesFamilies PhysicalPhysical

MappingMapping

andand

CloningCloning

FinerFiner

GeneticGenetic

MappingMappingLinkageLinkage

AnalysisAnalysis++

TranscriptTranscript

IdentificationIdentification

CandidateCandidatecDNAscDNAs

MutationMutation

SearchSearch

..A A C T C..A A C T C

..A A G T C..A A G T C

BACsBACs

NormalNormal

MutationMutation

GeneticGeneticMarkersMarkers

Page 19: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.
Page 20: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Marfan Syndrome -autosomal dominant disorder characterized by weakened connective tissue -most life-treatening is aortic dissection (an aneurysm of the aorta) -other symptoms include mitral valve prolapse, emphysema-like lung disease, and ocular and skin disorders -patients tend to be tall and lanky, with very long limbs, fingers and toes

Page 21: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Fibrillin 1 Gene Mutated in Marfan Syndrome Patients(A)Single-strand conformational polymorphism screen(B) DNA sequence

Page 22: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Letter

                                                                                                                                                        

Nature Genetics  33, 407 - 411 (2003) Published online: 24 February 2003;

Dysregulation of TGF-   activation contributes to pathogenesis in Marfan syndrome

Enid R. Neptune1, 2, Pamela A. Frischmeyer2, Dan E. Arking2, Loretha Myers2, Tracie E. Bunton3, Barbara Gayraud4, Francesco Ramirez4, Lynn Y. Sakai5 & Harry C. Dietz2, 6

Page 23: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

                                                                                              

 

Lung histopathology and morphometry of mice deficient in fibrillin-1.

Page 24: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

                                                                                                    

                Figure 3

Active TGF-B expression and signaling in lung tissue of mice deficient in fibrillin-1.

Page 25: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

                                                                                  

Neutralizing antibody to TGF- rescues lung maturation in mice deficient in fibrillin-1.

Page 26: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

                                                                                  

Mice deficient in fibrillin-1 have preserved lung cell proliferation but greater apoptosis.

Page 27: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Model

Fibrillin deficiency

TGF not sequestered

TGFB activated

Apoptosis in lung, bone overgrowth, etc.

A lesson: Structural matrix elements serve crucial regulatory roles in cytokine activation and signalling

Page 28: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Identification of Mendelian and complex trait genes 1980-2002

0

200

400

600

800

1000

1200

1400

1600

1800

1980 1985 1990 1995 2000

Year

Number of Mendelian genes

0

10

20

30

40

50

60

70

80

90

100

Number of complex trait genes

Mendelian traits

All complex traits

Human complex traits

Glazer, et al. (2002) Science

Page 29: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

                       

                      

•Ian

Page 30: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.
Page 31: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.
Page 33: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Nature Genetics  34, 383 - 394 (2003)

VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic deathDiether Lambrechts1, Erik Storkebaum1, Masafumi Morimoto1, Jurgen Del-Favero2, Frederik Desmet1, Stefan L Marklund3, Sabine Wyns1, Vincent Thijs1, Jörgen Andersson3, Ingrid van Marion4, Ammar Al-Chalabi5, Stephanie Bornes6, Rhiannon Musson4, Valerie Hansen5, Lars Beckman3, Rolf Adolfsson7, Hardev Singh Pall4, Hervé Prats6, Severine Vermeire1, Paul Rutgeerts1, Shigehiro Katayama8, Takuya Awata8, Nigel Leigh5, Loïc Lang-Lazdunski9, Mieke Dewerchin1, Christopher Shaw5, Lieve Moons1, Robert Vlietinck1, 10, Karen E Morrison4, Wim Robberecht1, Christine Van Broeckhoven2, Désiré Collen1, Peter M Andersen3 & Peter Carmeliet1

Page 34: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

                                                             

                                                            

VEGF Polymorphisms

Page 35: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

                                                            

Page 36: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.
Page 37: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

                                                                                          

Page 38: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.
Page 39: Genetics of Vascular Diseases Jake Lusis 3-730 MRL Jlusis@mednet.ucla.edu.

Lesson

Basic vascular biology studies (regulation of VEGF expression in response to hypoxia) can lead to an understanding of a complex disease